Nonalcoholic Fatty Liver Disease and HIV Infection

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome that includes a range of disorders associated with fatty liver from steatosis to cirrhosis and hepatocellular carcinoma, defined by the presence of liver fat accumulation exceeding 5% of hepatocytes in the absence of other causes of liver disease such as alcohol consumption, viral hepatitis, or any other specific etiology. Half the patients with human immunodeficiency virus (HIV) who undergo additional testing for unexplained liver test abnormalities may suffer from NAFLD, which is the hepatic manifestation of the metabolic syndrome. In HIV-infected patients, NAFLD can result from the HIV itself, highly active antiretroviral therapy (HAART), and/or lipodystrophy. Evaluation of the liver impact of NAFLD remains mainly based on liver biopsy, but numerous noninvasive procedures are under evaluation. In HIV/hepatitis C virus (HCV-) coinfected patients, steatosis seems more frequent and severe by comparison with HCV-monoinfected patients, and is associated with significant liver fibrosis, which may contribute to the more rapid progression of liver disease. First-line treatment of NAFLD is mainly based on the adequate management of the metabolic syndrome, including lifestyle changes. Specific therapeutic approaches are under investigation.

Keywords

fatty liver disease - human immunodeficiency virus - nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - metabolic syndrome

• References

• 1 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37 (5) 1202-1219
• 2 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55 (7) 434-438
• 3 Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19 (2) 221-229
• 4 Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. Hepatology 2010; 51 (2) 373-375
• 5 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40 (4) 578-584
• 6 Hui JM, Kench JG, Chitturi S , et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38 (2) 420-427
• 7 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51 (5) 1820-1832
• 8 Joint UN Programme on HIV/AIDS. 2006 Report on the global AIDS epidemic: a UNAIDS 10th anniversary special edition. Executive summary. Available at: http://data.unaids.org/pub/ GlobalReport/2006/2006_gr-executivesummary_en.pdf . Accessed February 9, 2010
• 9 Mocroft A, Brettle R, Kirk O , et al; EuroSIDA study group. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16 (12) 1663-1671
• 10 Weber R, Sabin CA, Friis-Moller N , et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166 (15) 1632-1641
• 11 Salmon-Ceron D, Lewden C, Morlat P , et al; Mortality 2000 study group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42 (6) 799-805
• 12 Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377 (9772) 1198-1209
• 13 Hu B, French SW. 2′,3′-Dideoxyinosine-induced Mallory bodies in patients with HIV. Am J Clin Pathol 1997; 108 (3) 280-283
• 14 Coglan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33 (11) 1914-1921
• 15 Duong Van Huyen JP, Landau A, Piketty C , et al. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. Am J Clin Pathol 2003; 119 (4) 546-555
• 16 Day CP, James OF. Steatohepatitis: a tale of two “hits”?. Gastroenterology 1998; 114 (4) 842-845
• 17 Lavoie JM, Gauthier MS. Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sci 2006; 63 (12) 1393-1409
• 18 Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009; 19 (4) 291-302
• 19 Parola M, Marra F. Adipokines and redox signaling: impact on fatty liver disease. Antioxid Redox Signal 2011; 15 (2) 461-483
• 20 Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010; 25 (4) 672-690
• 21 Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009; 9 (3) 299-314
• 22 Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin?. Hepatology 2004; 40 (1) 46-54
• 23 Sanyal AJ, Campbell-Sargent C, Mirshahi F , et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120 (5) 1183-1192
• 24 Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21 (1) 27-41
• 25 Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37 (1) 56-62
• 26 Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16 (4) 421-427
• 27 Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 2006; 290 (6) G1339-G1346
• 28 Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006; 291 (2) E275-E281
• 29 Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42 (6) 928-940
• 30 Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50 (3) 957-969
• 31 Marra F. Leptin and liver tissue repair: do rodent models provide the answers?. J Hepatol 2007; 46 (1) 12-18
• 32 Aleffi S, Petrai I, Bertolani C , et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42 (6) 1339-1348
• 33 Jiang JX, Mikami K, Shah VH, Torok NJ. Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism. Hepatology 2008; 48 (5) 1497-1505
• 34 Iwai M, Horiuchi M. Role of renin-angiotensin system in adipose tissue dysfunction. Hypertens Res 2009; 32 (6) 425-427
• 35 Moreno M, Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis 2008; 12 (4) 825-852 , ix
• 36 Kohlstedt K, Gershome C, Trouvain C, Hofmann WK, Fichtlscherer S, Fleming I. Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade. Mol Pharmacol 2009; 75 (3) 685-692
• 37 Crum-Cianflone N, Dilay A, Collins G , et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50 (5) 464-473
• 38 Guaraldi G, Squillace N, Stentarelli C , et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47 (2) 250-257
• 39 Mohammed SS, Aghdassi E, Salit IE , et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr 2007; 45 (4) 432-438
• 40 Ingiliz P, Valantin MA, Duvivier C , et al. Liver damage underlying unexplained transaminases elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49 (2) 436-442
• 41 Marks K, Petrovic L, Talal A , et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192 (11) 1943-1949
• 42 Laguno M, Milinkovic A, de Lazzari E , et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005; 10 (3) 423-429
• 43 Piroth L. Liver steatosis in HIV-infected patients. AIDS Rev 2005; 7 (4) 197-209
• 44 Hu KQ, Kyulo NL, Esrailian E , et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 2004; 40 (1) 147-154
• 45 Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36 (3) 729-736
• 46 Browning JD, Szczepaniak LS, Dobbins R , et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (6) 1387-1395
• 47 Rubbia-Brandt L, Quadri R, Abid K , et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33 (1) 106-115
• 48 Bani-Sadr F, Carrat F, Bedossa P , et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 2006; 20 (4) 525-531
• 49 Castéra L, Loko MA, Le Bail B , et al. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV-monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Ther 2007; 26 (11-12) 1489-1498
• 50 McGovern BH, Ditelberg JS, Taylor LE , et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infections in HIV-seropositive patients. Clin Infect Dis 2006; 43 (3) 365-372
• 51 Neau D, Winnock M, Castéra L , et al. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. . J Acquir Immune Defic Syndr 2007; 45 (2) 168-173
• 52 Rodríguez-Torres M, Govindarajan S, Solá R , et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008; 48 (5) 756-764
• 53 Sterling RK, Contos MJ, Smith PG , et al. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008; 47 (4) 1118-1127
• 54 Sulkowski MS, Mehta SH, Torbenson M , et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19 (6) 585-592
• 55 Kim AY, Chung RT. Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology 2009; 137 (3) 795-814
• 56 Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44 (6) 1026-1032
• 57 Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010; 52 (3) 71-78
• 58 Keithley JK, Duloy AM, Swanson B, Zeller JM. HIV infection and obesity: a review of the evidence. J Assoc Nurses AIDS Care 2009; 20 (4) 260-274
• 59 Amorosa V, Synnestvedt M, Gross R , et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005; 39 (5) 557-561
• 60 Lapadula G, Torti C, Paraninfo G , et al; EPOKa-A Study Group of the MASTER Cohort. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 2006; 11 (4) 521-527
• 61 Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34 (3) 428-434
• 62 Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42 (1) 44-52
• 63 Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25 (8) 883-889
• 64 Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12 (5) 1106-1110
• 65 Moyle G, Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials 2002; 3 (1) 89-98
• 66 Worm SW, Friis-Møller N, Bruyand M , et al; D:A:D study group. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24 (3) 427-435
• 67 Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005; 42 (2) 310-316
• 68 Sulkowski M, Mehta S, Montes de Occa R, Moore R, Thomas D. Estimated prevalence of significant liver disease among 4,052 HIV-infected adults with and without chronic hepatitis B and C. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, CO
• 69 DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re III V. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10: 116
• 70 Castellares C, Barreiro P, Martín-Carbonero L , et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15 (3) 165-172
• 71 Poynard T, Lebray P, Ingiliz P , et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40
• 72 Paradis V, Perlemuter G, Bonvoust F , et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34 (4 Pt 1) 738-744
• 73 Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30 (6) 1356-1362
• 74 Jaskiewicz K, Rzepko R, Sledzinski Z. Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig Dis Sci 2008; 53 (3) 785-788
• 75 Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42 (1) 132-138
• 76 Bhala N, Angulo P, van der Poorten D , et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54 (4) 1208-1216
• 77 Woreta TA, Sutcliffe CG, Mehta SH , et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140 (3) 809-817
• 78 Sterling RK, Wegelin JA, Smith PG , et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol 2010; 8 (12) 1070-1076
• 79 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (6) 1413-1419
• 80 Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344 (7) 495-500
• 81 Qayyum A, Chen DM, Breiman RS , et al. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best?. Clin Imaging 2009; 33 (2) 110-115
• 82 Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51 (3) 433-445
• 83 Lee SW, Park SH, Kim KW , et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology 2007; 244 (2) 479-485
• 84 Limanond P, Raman SS, Lassman C , et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004; 230 (1) 276-280
• 85 Park SH, Kim PN, Kim KW , et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239 (1) 105-112
• 86 Liu ZJ, Gong JP, Yan LN. Quantitative estimation of the degree of hepatic macrovesicular steatosis in a disease-free population: a single-center experience in mainland China. Liver Transpl 2009; 15 (11) 1605-1612
• 87 Shores NJ, Link K, Fernandez A , et al. Non-contrasted computed tomography for the accurate measurement of liver steatosis in obese patients. Dig Dis Sci 2011; 56 (7) 2145-2151
• 88 Hadigan C, Liebau J, Andersen R, Holalkere NS, Sahani DV. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr 2007; 46 (3) 312-317
• 89 Ghotb A, Noworolski SM, Madden E , et al. Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy. J Acquir Immune Defic Syndr 2010; 55 (2) 228-231
• 90 Poynard T, Ratziu V, Charlotte F , et al; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34
• 91 Zein CO, Edmison JM, Schluchter M, Feldstein AE, Zein NN, McCullough AJ. A NASH predictive index (NPI) for use in patients with non-alcoholic fatty liver disease. Hepatology 2007; 46 (Suppl 1) 747A
• 92 Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50 (4) 1072-1078
• 93 Musso G, Gambino R, Durazzo M, Cassader M. Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. Hepatology 2010; 51 (2) 715-717
• 94 Ratziu V, Massard J, Charlotte F , et al; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6
• 95 Angulo P, Hui J, Marchesini G , et al. The NAFLD fibrosis score: a non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 849-854
• 96 Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57 (10) 1441-1447
• 97 Guha I, Parkes J, Roderick P , et al. Noninvasive markers of fibrosis in non alcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology 2009; 47: 455-460
• 98 Calès P, Lainé F, Boursier J , et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50 (1) 165-173
• 99 Kelleher T, MacFarlane C, de Ledinghen V , et al. Risk factors and hepatic elastography (FibroScan) in the prediction of hepatic fibrosis in non-alcoholic steatohepatitis. Gastroenterology 2006; 130: A736
• 100 Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43 (8) 617-649
• 101 Castéra L, Foucher J, Bernard PH , et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51 (3) 828-835
• 102 de Ledinghen V, Fournier C, Foucher J , et al. New Fibroscan probe for obese patients. A pilot study of feasibility and performances in patients with BMI > 30 kg/m² . J Hepatol 2009; 50 (Suppl 1) 359
• 103 Joka D, Wahl K, Moeller S , et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012; 55 (2) 455-464
• 104 Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 2011; 17 (29) 3377-3389
• 105 Neuschwander-Tetri BA. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis 2009; 13 (4) 649-665
• 106 Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54 (3) 603-608
• 107 Tiikkainen M, Bergholm R, Vehkavaara S , et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003; 52 (3) 701-707
• 108 Suzuki A, Lindor K, St Saver J , et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005; 43 (6) 1060-1066
• 109 Promrat K, Kleiner DE, Niemeier HM , et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51 (1) 121-129
• 110 Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52 (1) 79-104
• 111 Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56 (4) 944-951
• 112 St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009; 50 (1) 68-76
• 113 Moscatiello S, Marzocchi R, Villanova N, Bugianesi E, Marchesini G. Which treatment for nonalcoholic fatty liver disease?. Mini Rev Med Chem 2008; 8 (8) 767-775
• 114 Lutchman G, Modi A, Kleiner DE , et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46 (2) 424-429
• 115 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49 (1) 306-317
• 116 Lavine JE, Schwimmer JB, Van Natta ML , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305 (16) 1659-1668
• 117 Sanyal AJ, Chalasani N, Kowdley KV , et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362 (18) 1675-1685
• 118 Lindor KD, Kowdley KV, Heathcote EJ , et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39 (3) 770-778
• 119 Yokohama S, Yoneda M, Haneda M , et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40 (5) 1222-1225
• 120 Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology 2011; 54 (5) 1631-1639
• 121 Ratziu V, Sheikh MY, Sanyal AJ , et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012; 55 (2) 419-428
• 122 Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22 (5) 634-638
• 123 Zein C, Yerian L, Cogate P , et al. Pentoxyfylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54 (5) 1610-1619
• 124 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/ContentFiles.AdultandAdolescentGL.pdf . Accessed March 1, 2012
• 125 Gallant JE, Staszewski S, Pozniak AL , et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292 (2) 191-201